by [email protected] | Dec 9, 2022 | Cardiovascular, Publication
Abstract This study evaluated effectiveness and safety of apixaban versus warfarin among venous thromboembolism patients at high-risk of bleeding (defined as having at least one of the following bleeding risk factors: ≥75 years; used antiplatelet, NSAIDs, or...
by [email protected] | Apr 28, 2022 | Cardiovascular, Publication
Abstract Background: Oral anticoagulants (OACs) mitigate the risk of stroke in atrial fibrillation (AF) patients. Objective: Elderly AF patients who were treated with OACs (apixaban, dabigatran, edoxaban, rivaroxaban, or warfarin) were compared against AF patients who...
by [email protected] | Jul 5, 2019 | Hematology, Hereditary Genetic, Publication
Abstract Authors: Nirmish Shah, Menaka Bhor, Lin Xie, Jincy Paulose, Huseyin Yuce Objectives: This study evaluated the prevalence rate of vaso-occlusive crisis (VOC) episodes, rates of uncomplicated and complicated VOC episodes, and the primary reasons for emergency...
by [email protected] | May 14, 2019 | Cardiovascular, Publication
Abstract Authors: Amin A, Garcia Reeves AB, Li X, Dhamane A, Luo X, Di Fusco M, Nadkarni A, Friend K, Rosenblatt L, Mardekian J, Pan X, Yuce H, Keshishian A Direct oral anticoagulants (DOACs) are at least as efficacious and safe as warfarin among non-valvular atrial...
by [email protected] | May 4, 2019 | Cardiovascular, Publication
Abstract Authors: Li X, Keshishian A, Hamilton M, Horblyuk R, Gupta K, Luo X, Mardekian J, Friend K,Nadkarni A, Pan X, Lip GYH, Deitelzweig S. Prior real-world studies have shown that apixaban is associated with a reduced risk of stroke/systemic embolism (stroke/SE)...
